Phase 1, Multicenter, Open-Label, Multiple-Dose Study of DS-8201a to Assess the Effect on the QT Interval, and Pharmacokinetics in Subjects with HER2-Expressing Metastatic and/or Unresectable Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2018
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Advanced breast cancer
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 30 Sep 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2018.
- 26 Sep 2018 Planned End Date changed from 30 Sep 2018 to 31 Mar 2020.
- 26 Sep 2018 Status changed from recruiting to active, no longer recruiting.